

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5652046

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Yuelel Shen	01/18/2019
Yang Bai	01/11/2019
Rui Huang	01/11/2019
Xiaofei Zhou	01/11/2019
Yuting Hu	01/11/2019
Yanan Guo	01/11/2019
Jichao Du	01/11/2019
RECEIVING PARTY DATA	
Name:	BEIJING BIOCYTOGEN CO., LTD.
Street Address:	88 KECHUANG 6TH AVE
Internal Address:	BDA BUILDING 3, RM 1207
City:	YIZHUANG, BEIJING
State/Country:	CHINA
Postal Code:	101111
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16313819
CORRESPONDENCE DATA	
Fax Number:	(877)769-7945
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617) 368-2124
Email:	hamm@fr.com, apsi@fr.com
Correspondent Name:	PENG LIN
Address Line 1:	FISH & RICHARDSON P.C.
Address Line 2:	P.O.BOX 1022
Address Line 4:	MINNEAPOLIS, MINNESOTA 55440-1022
ATTORNEY DOCKET NUMBER:	44835-0033US1
NAME OF SUBMITTER:	LYNDZIE HAMM
SIGNATURE:	/Lyndzie Hamm/

PATENT

DATE SIGNED:	08/05/2019
Total Attachments: 4 source=Assignment#page1.tif source=Assignment#page2.tif source=Assignment#page3.tif source=Assignment#page4.tif	

ASSIGNMENT


For valuable consideration, the receipt of which we acknowledge, and intending to be bound legally, we, YUELEI SHEN, YANG BAI, RUI HUANG, XIAOFEI ZHOU, YUTING HU, YANAN GUO, and JICHAO DU, each individually assign to BEIJING BIOCYTOGEN CO., LTD., a corporation having a principal place of business at 88 Kechuang 6th Ave. BDA, Building 3, Rm 1207, Yizhuang, Beijing, 101111, China, and its successors, transferees, and assignees (collectively the "Assignee"), all of our individual and joint right, title, and interest throughout the world in the invention(s) (the "Subject Matter") described in a patent application that names us as inventors, is titled "METHOD FOR CONSTRUCTING PD-1 GENE MODIFIED HUMANIZED ANIMAL MODEL AND USE THEREOF," and was or will be filed in the United States Patent and Trademark Office on December 27, 2018, as application 16/313,819 (the "Application").

This Assignment assigns, in addition to the Subject Matter of the Application, (a) the Application and all other applications that may be made for, and all patents, utility models, design registrations, and other rights of exclusion and inventors' certificates for, any of the Subject Matter (collectively the "Applications and Granted Rights") in every country or region and under every treaty or convention, (b) the right to claim priority based on and the benefit of the filing date of any of the Applications and Granted Rights under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other applicable treaties or conventions, and (c) the right to pursue, collect, and retain in the Assignee's name or otherwise, damages and any other remedies arising from any past, present, or future infringement of the Subject Matter, the Applications and Granted Rights, and any other rights assigned by this Assignment.

We authorize the Assignee to apply for and pursue protection for any or all of the Subject Matter, the Applications and Granted Rights, and any other rights assigned by this Assignment in all countries, regions, and territories of the world, in our names or in the Assignee's name.

We represent and warrant that we have the right and power to make this Assignment and that we have not made and will not make any other assignment that conflicts with this Assignment.

We will communicate to the Assignee (or, at the request of the Assignee to other parties) all known facts in any form relating to the Subject Matter; will execute and provide all oaths and declarations, statements, testimony, assignments, powers of attorney, applications, and documents; and will perform all other lawful acts necessary or desirable to secure fully to the Assignee the rights, titles, and interests assigned by this Assignment.


Yuelei Shen

Date: 1/18/2019

Witnessed by:

Signature: Zhifang Bai

Date: 1/18/2019

Print Name: Zhifang Bai

Signature: Yunzi Dong

Date: 1/18/2019

Print Name: Yunzi Dong


Yang Bai

Date: 1/11/2019

Witnessed by:

Signature: Zhifang Bai

Date: 1/11/2019

Print Name: Zhifang Bai

Signature: Yunzi Dong

Date: 1/11/2019

Print Name: Yunzi Dong

Rui Huang
Rui Huang

Date: 1/11/2019

Witnessed by:

Signature: Zhifang Bai

Date: 1/11/2019

Print Name: Zhifang Bai

Signature: Yunzi Dong

Date: 1/11/2019

Print Name: Yunzi Dong

Xiaofei Zhou
Xiaofei Zhou

Date: 1/11/2019

Witnessed by:

Signature: Zhifang Bai

Date: 1/11/2019

Print Name: Zhifang Bai

Signature: Yunzi Dong

Date: 1/11/2019

Print Name: Yunzi Dong

Yuting Hu
Yuting Hu

Date: 1/11/2019

Witnessed by:

Signature: Zhifang Bai

Date: 1/11/2019

Print Name: Zhifang Bai

Signature: Yunzi Dong

Date: 1/11/2019

Print Name: Yunzi Dong

Yanan Guo
Yanan Guo

Date: 1/11/2019

Witnessed by:

Signature: Zhifang Bai

Date: 1/11/2019

Print Name: Zhifang Bai

Signature: Yunzi Dong

Date: 1/11/2019

Print Name: Yunzi Dong

Jichao Du
Jichao Du

Date: 1/18/2019

Witnessed by:

Signature: Zhifang Bai

Date: 1/18/2019

Print Name: Zhifang Bai

Signature: Yunzi Dong

Date: 1/18/2019

Print Name: Yunzi Dong

The Assignee hereby acknowledges and accepts the foregoing assignment.

Assignee: BEIJING BIOCYTOGEN CO., LTD.

Signature: Yuelei Shen

Date: 1/18/2019

Name: Yuelei Shen

Title: President & CEO

11438457.doc